文献速递浆细胞疾病

新药时代巨灶型多发性骨髓瘤的真实世界研究

Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group.
PubMed 文献 · Am J Hematol · 2020-03-02

该研究基于希腊-以色列协作组数据,在4650例骨髓瘤患者中识别出140例巨灶型多发性骨髓瘤(MFMM),占3%。MFMM患者骨髓浸润有限但骨病进展,浆细胞瘤更常见,不良预后因素较少,90%接受新药治疗,总缓解率90%,中位无进展生存期46个月、总生存期129个月,均显著优于对照组。蛋白酶体抑制剂为基础的治疗是总生存期的唯一独立预测因素。

要点

  • MFMM占骨髓瘤患者3%,骨髓浆细胞<20%但骨病变进展,浆细胞瘤发生率68%。
  • MFMM不良预后因素较少,90%接受新药治疗,客观缓解率90%,≥非常好的部分缓解率70%。
  • 中位无进展生存期46个月、总生存期129个月,蛋白酶体抑制剂治疗为总生存独立预测因素。

核心结论

  • MFMM是一种独立实体,骨髓浸润有限但骨病进展、浆细胞瘤常见,不良预后因素较少,经新药尤其蛋白酶体抑制剂治疗可获得优异缓解和延长总生存。

研究设计与样本

  • 回顾性真实世界研究,基于希腊-以色列协作组数据,在4650例骨髓瘤患者中识别140例MFMM(占3%),并以两倍数量的典型骨髓瘤患者为对照。

主要发现

  • MFMM患者中60%年龄<65岁,70%有进展期骨病,浆细胞瘤发生率68%显著高于对照组的15%(P<.05)。
  • MFMM患者高乳酸脱氢酶、进展期分期、高危细胞遗传学、免疫麻痹等不良预后参数均较对照组少见(P<.05)。
  • 90%接受新药治疗,47% upfront接受自体移植,90%达客观缓解,70%达至少非常好的部分缓解,显著高于对照组(P<.05)。
  • 中位随访52个月,33例死亡,早期死亡(<12个月)少见;中位无进展生存期46个月、总生存期129个月,均显著长于对照组(P<.001)。
  • 多因素分析中,蛋白酶体抑制剂为基础的治疗是总生存期的唯一独立预测因素(HR: 3.9;P<.001)。

关键数值与推荐

  • MFMM定义:骨髓浆细胞<20%,存在溶骨性病变/浆细胞瘤,无贫血、肾功能不全或高钙血症。

临床怎么用

  • 对骨髓浆细胞负荷低但骨病进展、伴浆细胞瘤的患者应考虑MFMM,优先采用含蛋白酶体抑制剂方案治疗。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We investigated incidence, characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) treated mainly with novel therapies. Based on definition (BMPCs <20% and lytic lesions/plasmacytomas, without anemia, renal insufficiency or hypercalcemia) we identified 140 patients with MFMM, among 4650 myeloma patients (3%). Twice the number of patients with typical myeloma were used as controls; 60% were <65 years and 70% had advanced bone disease. Plasmacytomas were more frequent in MFMM compared with standard myeloma (68% vs 15%, P < .05). Adverse prognostic parameters (high lactate dehydrogenase, advanced stage, high risk cytogenetics, immunoparesis) were less common in patients with MFMM compared with controls (P < .05); 90% received novel agents and 47% underwent autologous transplantation upfront; 90% achieved an objective response; 70% had at least very good partial response which was significantly higher compared with controls (P < .05). After a median follow-up of 52 months, 33 patients have died. Early death (<12 months) was infrequent in MFMM. Median progression-free survival and overall survival (OS) were 46 and 129 months respectively, both significantly longer compared with controls (P < .001). Proteasome inhibitor (PI)-based therapy was the only independent predictor for OS in the multivariate analysis (HR: 3.9; P < .001). In conclusion, MFMM is a distinct entity presented in young and elderly subjects, characterized by limited bone marrow infiltration, advanced bone disease and frequent presence of plasmacytomas; MFMM patients have less often adverse prognostic features and achieve excellent responses and prolonged OS especially when treated with PI-based therapies. Novel imaging will help in a more accurate classification of this entity.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Katodritou E, Kastritis E, Gatt M, et al. Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group. Am J Hematol. 2020. PMID: 32048329. doi:10.1002/ajh.25755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。